https://orcid.org/0000-0002-8479-2775
References
- Martins AM, Valadares ER, Porta G, et al. Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. J Pediatr. 2009;155(4 Suppl):S10–S18.
- Nalysnyk L, Rotella P, Simeone JC, et al. Gaucher disease epidemiology and natural history: a comprehensive review of the literature. Hematology. 2017;22(2):755–73.
- Zimran A, Elstein D. Gaucher disease and related lysosomal storage diseases. In: Kaushansky K, Lichtman M, Prchal J, editors. Williams hematology. 9th ed. New York (NY): McGraw-Hill; 2016.
- Zimran A, Gelbart T, Westwood B, et al. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet. 1991;49(4):855–859.
- Kishnani PS, Al-Hertani W, Balwani M, et al. Screening, patient identification, evaluation, and treatment in patients with Gaucher disease: results from a Delphi consensus. Mol Genet Metab. 2022;135(2):154–162.
- Dinur T, Grittner U, Revel-Vilk S, et al. Impact of long-term enzyme replacement therapy on glucosylsphingosine (Lyso-Gb1) values in patients with type 1 Gaucher disease: statistical models for comparing three enzymatic formulations. IJMS. 2021;22(14):7699.
- Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med. 2002;113(2):112–119.
- Zimran A, Elstein D. Management of Gaucher disease: enzyme replacement therapy. Pediatr Endocrinol Rev. 2014;12(Suppl 1):82–87.
- CEREZYME [Prescribing information] [cited 2021 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/20367s066lbl.pdf
- Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol. 2004;41(4 Suppl 5):4–14.
- VPRIV [Prescribing information] [cited 2021 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022575lbl.pdf
- ELELYSO [Prescribing information] [cited 2021 Jan 25]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022458lbl.pdf
- Zimran A, Elstein D, Gonzalez DE, et al. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials. Blood Cells Mol Dis. 2018;68:153–159.
- Zimran A, Gonzalez-Rodriguez DE, Abrahamov A, et al. Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-naïve or previously treated with imiglucerase. Blood Cells Mol Dis. 2018;68:163–172.
- Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016;34(11):1111–1131.
- Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5–14.
- Deegan P, Fernandez-Sasso D, Giraldo P, et al. Treatment patterns from 647 patients with Gaucher disease: an analysis from the Gaucher outcome survey. Blood Cells Mol Dis. 2018;68:218–225.
- Nalysnyk L, Sugarman R, Cele C, et al. Budget impact analysis of eliglustat for the treatment of Gaucher disease type 1 in the United States. J Manag Care Spec Pharm. 2018;24(10):1002–1008.
- Fryar CD, Kruszon-Moran D, Gu Q, et al. Mean body weight, height, waist circumference, and body mass index among adults: United States, 1999–2000 through 2015–2016. Natl Health Stat Report. 2018;(122):1–16.
- Academy of Managed Care Pharmacy (AMCP). Managed care glossary 2022 [cited 2022 May 3]. Available from: https://www.amcp.org/about/managed-care-pharmacy-101/managed-care-glossary
- Academy of Managed Care Pharmacy (AMCP). AMCP guide to pharmaceutical payment methods; Executive summary version 3.0 2013 [cited 2022 May 4]. Available from: https://www.amcp.org/sites/default/files/2019-03/MM%20edits-Executive_Summary%20%28final-mar27%29_MB.pdf
- Revel-Vilk S, Szer J, Mehta A, et al. How we manage Gaucher disease in the era of choices. Br J Haematol. 2018;182(4):467–480.
- Biegstraaten M, Cox TM, Belmatoug N, et al. Management goals for type 1 Gaucher disease: an expert consensus document from the European Working Group on Gaucher disease. Blood Cells Mol Dis. 2018;68:203–208.
- European Medicines Agency. Gaucher disease: a strategic collaborative approach from EMA and FDA. London, United Kingdom; 2014 [cited 2021 Sep 29]. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/gaucher-disease-strategic-collaborative-approach-european-medicines-agency-food-drug-administration_en.pdf
- Limgala RP, Ioanou C, Plassmeyer M, et al. Time of initiating enzyme replacement therapy affects immune abnormalities and disease severity in patients with Gaucher disease. PLOS One. 2016;11(12):e0168135.